Natco Pharma and its co-development and marketing partner Dr. Reddy’s Laboratories have filed for Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil, for intravenous use, for the European Markets.

Janssen’s brand Doxil is predominantly used for the treatment of metastatic breast cancer, advanced ovarian cancer and progressive multiple myeloma. The Doxil brand, 2mg/ml, had sales of around $130.5 million, in Europe, for the 12 months ending December 31, 2017, according to Quintiles IMS.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.